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Abstract The core pathogenic process in the common
marmoset model of multiple sclerosis (MS) is the
activation of memory-like T cells specific for peptide
34 to 56 derived from the extracellular domain of
myelin/oligodendrocyte glycoprotein (MOG34-56). Immu-
n i z a t i o nw i t hM O G 34-56 in incomplete Freund’s adjuvant
is a sufficient stimulus for in vivo activation of these T
cells, together with the induction of MS-like disease and
CNS pathology. Ex vivo functional characteristics of
MOG34-56 specific T cells are specific cytolysis of peptide
pulsed target cells and high IL-17A production. To
indentify possible functions in this new model of T helper
1 cells, which play a central pathogenic role in MS models
induced with complete Freund’s adjuvant, we tested the
effect of human interferon-γ (IFNγ) administration during
disease initiation of the disease (day 0–25) and around the
time of disease expression (psd 56–81). The results show a
clear modulatory effect of early IFNγ treatment on
humoral and cellular autoimmune parameters, but no
generalized mitigating effect on the disease course. These
results argue against a prominent pathogenic role of T
helper 1 cells in this new marmoset EAE model.
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Introduction
Experimental autoimmune encephalomyelitis (EAE) is a
well-established animal model of the human central
nervous system (CNS) targeting the neuroinflammatory
disease multiple sclerosis (MS). Various versions of the
model are being used to investigate immunopathogenic
mechanisms in MS and to develop new therapies. In
response to the need of an EAE model with high
relevance to MS in which biological therapeutics can be
tested, we have set up an EAE model in the Neotropical
primate “common marmoset” (Callithrix jacchus). The
model that was induced by sensitization against human
myelin or the immunodominant component myelin/
oligodendrocyte glycoprotein (MOG) and its advantage
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Analogous to EAE models in lower species, such as
mice and rats, T helper 1 (Th1) cells have a central
pathogenic role in marmoset EAE models induced with
recombinant human myelin/oligodendrocyte glycoprotein
(rhMOG) in complete Freund’s adjuvant (CFA) (Brok et
al. 2000). Accordingly, antibodies against human CD40, a
co-stimulatory molecule of antigen presenting cells in-
volved in the induction of IL-12, or against IL-12p40
subunit displayed strong suppressive activity, both in a
prophylactic (Boon et al. 2001;B r o ke ta l .2002; Laman et
al. 2002) and in a therapeutic experimental setting (‘tH a r t
et al. 2005a; b). However, the recent failure of the anti-IL-
12p40 antibody (Ustekinumab) in a phase II clinical trial
in relapsing-remitting MS points at an important discrep-
ancy with MS (Segal et al. 2008). The question is
therefore warranted whether the pathogenic role of Th1
cells in MS is comparable to that in EAE models.
We hypothesize that the dominant pathogenic role of
Th1 cells in EAE models can be attributed to the use of
CFA (Billiau and Matthys 2001). This would imply that
EAE models induced without use of CFA are less
sensitive to reagents that modulate Th1 functions.
Interferon-gamma (IFNγ) is the principal Th1 cytokine
induced by IL-12 and has consistently been found to be
protective in mouse models of EAE (Willenborg et al.
1999). In a mouse model, we showed that IL-12 sup-
pressed disease when administered systemically during the
early phase of EAE induction (Gran et al. 2004). The
suppressive effect was dependent on IFNγ,a si tw a sn o t
observed in IFNγ-deficient mice. Moreover, genetic
deficiency or antibody neutralization of IFNγ consistently
exacerbates EAE (Sanvito et al. 2010). On the other
hand, in another mouse model, IL-12 given during the
remission phase after the first attack induced more
severe relapses, and restored EAE susceptibility in mice
in which CD40-CD40 ligand interaction had been
blocked. However, it is not known whether these effects
are mediated by IFNγ (Constantinescu et al. 1999).
The aim of the current study was to test the activity
of human IFNγ in a recently developed marmoset EAE
model that is induced without usage of CFA, namely by
immunization with a synthetic peptide representing the
sequence 34 to 56 of human MOG (MOG34-56)
formulated in incomplete Freund’s adjuvant (IFA) (Jagessar
et al. 2010). The development of characteristic MS-like
clinical and pathological features in this model is driven
by CD3
+CD4
+/CD8
+CD56
+CD16
- T cells that display
high IL-17A production and antigen-specific cytolysis as
activities potentially contributing to EAE development
(Jagessar et al. 2010). We have examined the effect of
human IFNγ administration during two periods, namely
an early treatment period from the time of immunization
to post sensitization day (psd) 25 and a late treatment
period from psd 56 to 81. The primary outcome
measures were the susceptibility to, and the severity of
clinical EAE. Secondary and exploratory outcome
measures included immunological parameters and histo-
logical evidence of disease activity.
The data show a modulatory effect of early IFNγ
treatment on cellular as well as humoral autoimmune
parameters, yet with only a marginal effect on the disease
course. This finding argues against a generalised pathogenic
role of the IL-12/IFNγ axis in the marmoset EAE model
induced with MOG34-56/IFA.
Materials and methods
Animals
Fifteen healthy marmoset monkeys (Callithrix jacchus)
were included in this study originated from purpose-bred
colonies of the Biomedical Primate Research Centre
(BPRC), Rijswijk, The Netherlands, and the German
Primate Centre (DPZ), Göttingen, Germany. Monkeys
purchased from DPZ had been housed for at least 6 months
in the BPRC before use. Individual data of the monkeys
used in this study are listed in Table 1. Before inclusion in
the study, the monkeys were subjected to a complete
physical, hematological and biochemical examination.
During the study they remained under veterinary care.
Monkeys were pair-housed in spacious cages enriched
with branches and toys and with padded shelter provided
on the floor. The daily diet consisted of commercial food
pellets for New World monkeys (Special Diet Services,
Witham, Essex, UK), supplemented with rice, raisins,
peanuts, marshmallows, biscuits, fresh fruit, grasshoppers,
and maggots. Drinking water was provided ad libitum.
Ethics
In accordance with the Netherland’s law on animal
experimentation, all study protocols and experimental
procedures were reviewed and approved by the Institute’s
Ethics Committee before the start of experiments.
EAE induction
Synthetic MOG peptides based on the human MOG
extracellular sequence, which were used for immunization
and cell culture, were purchased from Cambridge Research
Biochemicals (Cleveland, UK).
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(Vétoquinol S.A., Magny-Vernois, France) and were immu-
nized with an emulsion of 100 μgM O G 34-56 dissolved in
300 μl buffered saline with 300 μl IFA (Difco Laboratories,
Detroit, MI). The inoculum was injected into the inguinal
and axillary regions of the dorsal skin divided over 4 spots of
150 μl each. Antigen-adjuvant emulsions were prepared by
gentle stirring the peptide/oil mixture at 4°C for at least 1 h.
Monkeys that failed to develop serious neurological deficit
(EAE score≥2.0) were again immunized at psd 28 and 56
with the same dose of peptide in IFA.
Treatment schedule
Clinical grade recombinant human IFNγ (Immukin
®) was
purchased from Boehringer Ingelheim, Vienna, Austria.
Biological activity in the marmoset system was confirmed
by increase of MHC class II expression on marmoset
PBMC (Suppl. Fig. 1).
Three groups of 5 animals each were randomly created
and as outlined in Fig. 1. Power calculation was used to
calculate the minimal group size for statistical evaluation
(Mann–Whitney U test). Based on historical data we
assumed a 100% disease incidence. To achieve a statistical
power of 80% the group size should be 5. The control
group received 3 subcutaneous injections per week (Mon,
Wed, Fri) of buffered saline (1.0 ml/kg) during two
treatment episodes from psd 0–25 and psd 56–81. The
early IFNγ treatment/prophylactic group) and the late IFNγ
treatment/therapeutic group) received 3 subcutaneous test
substance injections at a dose of 1.5μg/kg (1.0 ml/kg) per
week during psd 0–25 and psd 56–81, respectively.
Clinical scoring
Clinical signs were scored daily by two independent
observers as described (‘tH a r te ta l .1998). Briefly: 0=
no clinical signs; 0.5=apathy, loss of appetite, altered
walking pattern without ataxia; 1=lethargy, anorexia,
Fig. 1 Design of experiment. Fifteen marmosets of either sex were
randomly divided over 3 groups, 5 animals in each group (see table 1).
All marmosets were immunized with MOG34-56 in IFA and were re-
challenged at days 25 and 56. The first group (control) received only
solvent of the drug recombinant human IFNγ between post sensiti-
zation day (psd) 0–25 and psd 56–81. The second group (prophylactic
treatment) received three subcutaneous injections of human IFNγ
(1.5μg/kg) per week (Mon-Wed-Fri) between psd 0–25; the third
group (therapeutic treatment) received the same injection schedule
between psd 56–81
Table 1 Overview of
marmosets used in this study
aAge in months at the start of
the experiment; F, female; M,
male; psd, post sensitization day
Score 2.0=ataxia; score
2.25=incomplete paralysis of
hind limbs
Group Name Sex Age
a Sacrificed (psd) Score 2.0 Score 2.25
Control M06054 F 32 99 56 95
M07009 M 28 91 86 90
M07034 F 25 113 93 101
M07076 F 22 154 >154 >154
Mi12699 M 59 133 100 108
Mean±SD 118±26 98±36 110±26
rhIFN-γ M04014 F 64 154 >154 >154
Day0-25 M06036 M 35 133 127 128
M07062 F 23 57 51 54
M07101 F 20 135 119 120
Mi13264 M 41 144 138 143
Mean±SD 125±39 118±40 120±39
rhIFN-γ M06063 M 32 127 100 110
Day56-81 M07016 F 26 81 72 77
M07035 F 25 155 >155 >155
M07047 F 24 57 44 55
Mi12700 M 59 155 >155 >155
Mean±SD 115±44 105±50 110±45
J Neuroimmune Pharmacol (2012) 7:253–265 255loss of tail tonus, tremor; 2=ataxia, optic disease; 2.5=
para- or monoparesis, sensory loss, brain stem syn-
drome; 3=para- or hemiplegia; 4=quadriplegia; 5=
spontaneous death attributable to EAE. Monkeys were
sacrificed for ethical reasons once complete paralysis of
one or both hind limbs (score≥3.0) was observed, or at
a pre-determined endpoint.
Body weight, measured three times per week, served as
an objective surrogate disease marker. Weighing was
performed without sedation using the perspex cylinder:
adequately trained monkeys were captured from the home
cage.
Necropsy
Monkeys selected for necropsy were first deeply sedated by
intramuscular injection of alfaxan (10 mg/kg). Maximum
blood volume was collected into heparinized vacutainers
and subsequently the marmoset was euthanized by infusion
of pentobarbital sodium (Euthesate
®; Apharmo, Duiven,
The Netherlands).
Spleen and several lymph nodes were collected asepti-
cally and cut into four pieces, which were used for cell
culture or stored in 4% formalin, -80°C, and RNAlater
(Sigma, St. Louis, MO). Half of the brain and spinal cord
were stored in 4% formalin and the other half were snap-
frozen in liquid nitrogen.
Cell preparation
The maximum monthly blood volume that can be collected
from marmosets is 1% of the body weight, which is 3.5 –
4.0 ml for an average adult monkey of 350–400 g. Longitu-
dinal immune monitoring was performed using 1.5 ml venous
blood collected at 2 weeks interval from the femoral vein into
heparinized vacutainers (Greiner, Sölingen, Germany).
At necropsy mononuclear cell (MNC) suspensions were
prepared from aseptically removed spleen and axillary
(ALN), inguinal (ILN), cervical (CLN) and lumbar (LLN)
lymph nodes. MNC and PBMC were isolated using
lymphocyte separation medium (LSM
®, ICN Biomedical
Inc., Aurora, OH).
Proliferation of T cells
PBMC and lymphoid organ MNC suspensions were assayed
in triplicate for proliferation against rhMOG (10 μg/ml) and a
panelofMOGpeptides(each10μg/ml)(Jagessaretal.2010).
Proliferation was assessed by the incorporation of [
3H]-
thymidine (0.5 μCi/well) during the final 18 h of 64 h culture
using a matrix 9600 β-counter (Packard 9600; Packard
Instrument Company, Meriden, CT). Results are expressed
as stimulation index (SI), being the ratio of radiolabel
incorporation in stimulated versus unstimulated cultures. SI
values above 2.0 were considered positive.
Flow cytometry
Cells were phenotyped as described previously (Jagessar et
al. 2010). Flow cytometric analysis was performed on a
FACS LSRII flow cytometer using FACSDiva software 5.0
(BD Biosciences).
Cytokines
Supernatants of PBMC, ALN, and spleen MNC were
collected after 48 h stimulation with rhMOG or a panel of
overlapping MOG peptides. Supernatants were assayed
according to manufacturers instructions with commercial
ELISA kits for monkey IL-10, monkey IFNγ (U-Cytech,
Utrecht, The Netherlands) and human IL-17A (eBioscience,
San Diego, CA).
Quantitative PCR
Total RNAwas extracted from PBMC, spleen and ALN using
RNeasy minikit (Qiagen, Hilden, Germany) and subsequently
cDNA was synthesized using RevertAid First Strand cDNA
Synthesis Kit (Fermentas, St. Leon-Rot, Germany) according
to the manufacturer's instructions. Random hexamer primers
were used for cDNA synthesis. Quantitative PCR was
performed in duplicate using a using iTaq supermix
with ROX and CFX96 Real-Time System (both from
Bio-Rad, Hercules, CA). The primers (Invitrogen) and
probes (purchased from the Universal Probe Library
set for human, Roche, Indiapolis, In) used are listed in
Table 2. mRNA expression of tested primers was
related to mRNA expression of the reference gene
ABL (2
Ct reference – Ct target).
Autoantibody detection
Plasma samples were analyzed for IgG and IgM
antibody binding to rhMOG or to a panel of over-
lapping 23-mer pMOG sequences using ELISA as
described (Boon et al. 2001); (Jagessar et al. 2008).
Bound IgG and IgM were detected using polyclonal
alkaline phosphatase-conjugated rabbit-anti-human IgG
(Abcam, Cambridge, UK) or goat-anti-monkey IgM
(Rockland, Gilbertsville, PA). Antibody binding was
measured at 405 nm and results are expressed in arbitrary
units (AU) using the software ADAMSEL (developed by
Dr. E. Remarque, Biomedical Primate Research Centre,
Rijswijk, The Netherlands).
256 J Neuroimmune Pharmacol (2012) 7:253–265Table 2 Primers with
corresponding probes used for
quantitative PCR
Gene Forward primer Reverse primer Probe
ABL CAGAGAAGGTCTATGAACTCATGC GGTGGATTTCAGCAAAGGAG 86
IL-1β TGGTCCTAAACAGATGAAGTGC GTAGTGCTGGCGGGAGAGT 85
IL-2 AAGTTTTACATGCCCAAGAAGG AAGTGAAAGTTTTTGCTTTGAGCTA 65
IL-10 GTTGCCTTCAGCAGAGTGAA GCAACCCAGGTAACCCTTAAA 67
IL-17A CCTCATTGGTGTCACTGCTG TGCAATTCCTGCCTTCACTA 146
IFNγ GGAGAGAGGAGGGTGACAGA TTGGATGCTCTGGTTGTCTTTA 21
TNFα GGACGAGCTCTCCAAGGACT GTCACTCGGGATTCGAGAAG 81
CD3 AGGCAAGAGTGTGTGAGAACTG GATGCAGATGTCCACTATGACAA 10
CD4 TCTGTGAAGTGGAGAGCAAAAA TGACAGTCAATCCGAACACC 10
CD8 TCATGTACTTCAGCAGCTTCG GCTCTGGTGTGGGTGGTC 4
Fig. 2 Clinical scores and body weights of all animals. Marmoset
monkeys (n=15) were immunized with MOG34-56 in IFA and
subsequently treated for a period of 25 days with recombinant
human interferon-gamma by intravenous injection at a frequency of
3 times per week (see Fig.1). a The period of IFN-γ treatment is
shown as grey shaded areas. The control group received only the
solvent of IFN-γ.L e f ty - a x i s( solid line) indicates clinical scores and
right y-axis (dotted line) the percentage body weight loss relative to
day 0 as a surrogate disease marker. On the x-axis time after
immunization is plotted as post sensitization day. Arrowheads
indicate day of booster-immunizations with MOG34-56 in IFA.
M07062, M06054 and M07016 were boosted only once. PSD; post
sensitization day. b Survival curves are shown where the control
g r o u pi sc o m p a r e dt ot h eI F N - γ treatment groups. In the left panel
time to EAE score 2.0 and in the right panel time to the ethical end-
point (EAE score 3.0) is depicted
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Formalin-fixed brain sections were used for histological
examination as described previously (‘t Hart et al. 1998;
Jagessar et al. 2008; 2010). For quantification of demye-
lination 8 brain sections, in total 6 cm
2, were stained with
Luxol fast blue – periodic acid Schiff (LFB-PAS). The
Scion Image Program (NIH, USA) was used to calculate
the amount of demyelination per mm
2 as total of the white
and grey matter. Another set of 8 brain sections was stained
with hematoxylin and eosin and CD3 to determine the
amount of inflammation.
Statistical analysis
A high variation of the disease course and associated immune
parameters between individual animals is inherent to the
outbred nature of this model. Where possible data were
258 J Neuroimmune Pharmacol (2012) 7:253–265analyzed using the Mann–Whitney U test; p values<0.05
are considered to be significant.
Results
Human IFNγ has a variable effect on the disease course
in MOG34-45 induced EAE
Fifteen unrelated marmosets from an outbred colony were
randomized over three experimental groups of 5 monkeys
each (see Table 1), the group size was determined by power
calculation (see Materials and Methods) (Bacchetti et al.
2011). EAE was induced by immunization with human
MOG34-56 in IFA. Despite the absence of ligands of innate
receptors for antigen presenting cell activation this proce-
dure has induce clinically evident EAE in almost all tested
monkeys. Sometimes a case is found without evident
neurological signs within the predetermined observation
period, but such cases do display the characteristic CNS
pathology. Human IFNγ was administered during
25 days between the first and second immunization
(psd 0–25), modeling a prophylactic treatment regimen,
o rf o r2 5d a y sa f t e rp s d5 6( p s d5 6 –81), modeling
therapeutic treatment (Fig. 1).
The results are expressed as clinical course of individual
animals, demonstrating that in each group 1 monkey did
not display evident neurological deficit (Fig. 2). Besides, a
second monkey in the therapeutic group (Mi12700) did
not show neurological symptoms but suffered from
weight loss. The actual survival times of individual
animals depicted in table 1 show that the time interval to
the first symptom of overt neurological disease (ataxia;
score 2.0) was delayed from 98 to 118 days by early
treatment with IFNγ and from 98 to 105 days in monkeys
receiving late treatment with IFNγ.T w op a r a m e t e r sw e r e
statistically analyzed, namely disease-free survival (time
to EAE score 2.0) and overall survival (time to the ethical
end-point: score 3.0) (Fig. 2b). The survival curves show
that neither the prophylactic, nor the therapeutic treatment
with IFNγ had a consistent positive effect on the disease
course.
Demyelination and inflammation in brain
Pathological differences between the three groups were
examined by histology and immunohistochemistry. As
representative example of the control group and IFNγ
treated group, respectively, M07034 and M07035 are
shown in Fig. 3. Brain sections in both animals showed
demyelinated areas populated by activated macrophages
that contain degraded myelin products and by infiltrated
CD3
+ T cells. Demyelinated lesions were also observed in
the optic tract and in the corpus callosum. Interestingly,
Granzyme B staining detected some cytotoxic T cells.
Quantification of the amount of inflammation and
demyelination in brain for each animal (Fig. 3n),
revealed no differences in the intensity of demyelination
between the control and IFNγ treated groups. However,
inflammation tended to be less intensive in the late
treatment group (psd 56–81) although differences were
not statistically significant.
Modulation of humoral immunity by IFNγ
Immunization with MOG34-56 in CFA or IFA induces IgM
and IgG antibodies binding to ELISA-plate bound
overlapping peptides, i.e. MOG24-46 and MOG34-56,b u t
not to rhMOG protein (Jagessar et al. 2008), (2010).
Results of the analysis of serial immune sera from the
current experiment are depicted in supplementary Fig. 2.
The data from individual monkeys and the mean areas
under the curve (AUC) show that the highest IgM
antibody levels against both peptides were measured in
the early (psd 0–25) IFNγ treated animals, although
differences between the groups were not statistically
significant. Figure 4a shows that IgG antibody levels
against both peptides were significantly reduced in early
Fig. 3 Inflammation and demyelination in the brain characterized by
histology and immunohistochemisty. a-j Brain of M07034 as a
representative of the control group. a A low magnification scan from
a Kluver-Barrera (KLB) stained section (bar: 5 mm). The encircled
area represents the demyelinated optic tract, which is depicted
enlarged in b (bar: 500 μm). c Luxol fast blue - periodic acid Schiff
(LFB-PAS) staining shows in the optic tract the presence of macro-
phages with intracellular myelin degradation products (bar: 50 μm). d
Immunostaining for CD3 reveals the presence of some single T cells
in the optic tract (bar: 50 μm). e Another brain slice of M07034
stained for KLB (bar: 5 mm) is shown. The lower rectangle shows
demyelination in the corpus callosum that is enlarged in f and contains
LFB-PAS positive macrophages (bar: 500 μm). g Immunostaining for
myelin proteolipid protein (PLP) shows macrophages containing PLP
degraded products (bar: 25 μm). h A single Granzyme B positive
cytotoxic T cell is shown in the corpus callosum (bar: 20 μm). The
upper rectangle in e shows a cortical area that is shown enlarged in i
(bar: 250 μm) and in a PLP staining reveals subpial demyelination.
The rectangle in I shows the edge of the lesion, which is enlarged in
the insert. j Although no PLP positive degradation products are
present, staining for macrophage/microglia marker Iba-1 identifies
increase of microglial cells at the border of the subpial lesion (bar:
250 μm). k A low magnification scan of a KLB stained section from
M07035 as representative of the late IFNγ treated group. The
encircled area again shows the optic tract, which is only partially
demyelinated and enlarged in l (bar: 500 μm). m Further enlargement
of L reveals the presence of macrophages with myelin degraded
products (bar: 25 μm). n For each animal in the three groups
8 brain sections were analysed, which is comparable with 6 cm
2 in
total. The amount of infiltrated cells per mm
2 in the brain is given.
Same quantification is done for the amount demyelination in the
brain. A detailed description of the calculation is given in ‘Material
and Methods’
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trations, which were calculated for the four time blocks, i.e.
the no-treatment interval (psd 28–56). Summarizing, early
treatment with IFNγ resulted in suppressed IgG anti-
body production, whereas IgM antibody levels were not
affected by the treatment.
Modulation of cellular immunity by IFNγ
The modulation of cellular immunity in the model was
examined with two ex vivo assays, namely antigen-induced
proliferation and cytokine induction.
Proliferation of PBMC during the EAE course Every
14 days PBMC were collected and tested for proliferation
against MOG34-56 or rhMOG. As shown in Fig. 5a
responses against MOG34-56 were much stronger than
against rhMOG and the highest responses were measured
in the control monkeys from group 1. SI values>2.0 were
regarded as positive. Interestingly, Fig. 5b shows that early
treatment with IFNγ significantly prolonged the time to
reach SI values of 3.0, whereas this was not observed for
the late treatment group.
Proliferation of PBMC and lymphoid organ MNC at
necropsy Our previous study demonstrated that only a
minor quantity of the T cells proliferating against anti-
MOG34-56 is present in blood, and that the vast majority
can be found in the lymphoid organs. Hence we also
tested the antigen reactivity of several secondary lym-
phoid organs collected at necropsy, namely spleen, the
ALN and ILN that drain the immunization sites, and the
LLN and CLN that respectively drain the spinal cord and
brain.
It is of note that the proliferation data at necropsy
did not provide an explanation for the absence of
Fig. 4 Plasma IgG and IgM antibody binding to MOG peptides.
Longitudinally collected plasma samples (2 weeks interval and at
necropsy) were tested for the presence of IgG and IgM binding to
ELISA plates coated with a panel of overlapping MOG peptides. Only
antibodies binding to MOG24-46 and MOG34-56 were detected. a IgG
plasma levels were compared during and after the treatment periods to
assess whether there is a significant difference in antigen binding.
Data are processed with ADAMSEL and expressed in arbitrary units
(AU). b IgM antibody responses were only compared from day 0–56.
Data are expressed in area under curve (AUC), which is calculated
from data of Suppl. Fig. 2. *p<0.05, Mann–Whitney U test was used
as statistical calculation. Data are presented as mean ± SEM
260 J Neuroimmune Pharmacol (2012) 7:253–265neurological signs in the EAE affected control monkey
M07076. This monkey’s proliferation profile was similar
to that of control monkey Mi12699, which did develop
clinical EAE. By contrast, the proliferation was markedly
suppressed in monkeys from both IFNγ-treated groups
that did not develop overt neurological disease, i.e.
M04014 and M07035. Overall the results show that the
proliferation profiles of individual monkeys differ
markedly within each group (data not shown), but that
there are no obvious differences between the three
groups (Fig. 5c). These data suggest that IFNγ treatment
did not exert a consistent positive or negative effect on T
cell responses.
Cytokines
The main induced cytokine by ex vivo stimulation of
PBMC with MOG34-56 or rhMOG was IL-17A, as
Fig. 5 T-cell proliferation against MOG34-56 and rhMOG. Mononu-
clear cells (MNC) isolated from venous blood (PBMC) or various
lymphoid organs were probed for their proliferative response against
MOG34-56 and rhMOG. Proliferation was quantified as the incorpo-
ration of [
3H]-thymidine in the final 18 h of 3 days culture. All data
are expressed as stimulation index (SI) relative to unstimulated
cultures. SI above 2 (dotted line) is considered positive. a Longitu-
dinal reactivity of PBMC to MOG34-56 (left panel) and rhMOG (right
panel) is shown. b Time to a stimulation index (SI) of 3.0 against
MOG34-56 in blood was compared between the control group and IFN-
γ treated groups. Log-rank was used to calculate p-value. c At
necropsy MNC were prepared from blood, spleen, axillary (ALN),
inguinal (ILN), lumbar (LLN), and cervical (CLN) lymph nodes. Only
proliferation data from cultures stimulated with MOG34-56 are shown.
Mann–Whitney U test was used as statistical calculation. Data are
presented as mean ± SEM
J Neuroimmune Pharmacol (2012) 7:253–265 261measured by ELISA based on cross-reactive reagents. This
was confirmed in the current study (Suppl. Fig. 3).
Expression profiles of IL-17A, IFNγ or IL-10 did not
differ significantly between the three groups, although IL-
17A production after the first (psd 0) and third immuniza-
tion (psd 56) was consistently observed in the monkeys that
received IFNγ treatment. To investigate this further we
performed qPCR analysis of mRNA transcripts extracted
from PBMC, spleen and ALN for a broader range of
cytokines (Fig. 6a). The qPCR analysis showed no differ-
ences in cytokine expression between IFNγ-treated groups
and the control group. However, transcript levels differed
statistically between the organs (PBMC, spleen and ALN),
mainly for IL-10, IL-1β,T N F α and IL-2. A higher
expression of IL-10 and TNFα was detected in spleen and
ALN compared to PBMC in all three groups. The opposite
effect was observed for IL-1β, i.e. a higher expression in
PBMC than in ALN or spleen. Level of expression of IL-2
was only higher in ALN compared to PBMC and spleen.
Differences for the other two tested cytokines, IFNγ and
IL-17A, were less explicit.
Discussion
The optimal immunotherapy for MS selectively targets only
the immune processes that cause the progressive accumu-
lation of neurological deficit, while sparing immune
functions protecting against infections or tumorigenesis
(Feldmann and Steinman 2005). In the past years we have
dissected the core pathogenic autoimmune factor against
human CNS myelin in a unique EAE model in marmosets.
The well-documented clinical and pathological similarity
with MS is particularly relevant for translational research
into pathogenic mechanisms as well as for therapy
development (‘t Hart et al. 2004; 2006).
The original model was induced by immunization with
CNS myelin from human MS patient emulsified in CFA
(‘tH a r te ta l .1998). The discovery that autoimmunity
against MOG is essential for the induction of clinically
evident EAE (‘tH a r te ta l .1998) led us to develop a
reproducible disease model induced with rhMOG protein
in CFA. Subsequent fine-specificity analysis revealed that
the progression rate to full-blown clinical disease was
associated with the activation of CD3
+CD4
+/8
+CD56
+
cytotoxic T cells specific for MOG34-56 (Kap et al. 2008).
The strong clinical effect of antibodies against human
CD40 and against the shared p40 subunit of IL-12 and
IL-23 underlined the important role of the CD40/IL-12/23
axis in the rhMOG-induced EAE model in marmosets
(Boon et al. 2001; ‘tH a r te ta l .2005a, b). Up to that
point, the marmoset EAE model reproduced the essential
pathogenic features of rodent EAE models.
However, further research led to the unexpected
finding that immunization with MOG34-56 in IFA could
also induce full-blown clinical EAE (Jagessar et al. 2010).
The immunopathogenic mechanism of this new model
was found to be driven by T cells that are activated
without involvement of the otherwise required Toll-like
receptor ligands and which induce widespread CNS
demyelination in the absence of antibodies binding
MOG protein. Fine-specificity analysis of this model
revealed a central role of T cells specific for MOG
peptide 40–48 with a remarkable phenotype, namely
CD3
+CD4
+CD8
+CD16
-CD27
+CD28
-CD45RO
-.T h e
MOG34-56 specific T cell lines generated from this model
shows two immunological hallmarks i.e. high IL-17A
production and specific cytolytic activity towards peptide
presented via Caja-E molecules expressed by EBV-
transformed autologous B-lymphoblastoid cells (Jagessar
et al. 2011,i np r e s s ) .
These features clearly distinguish the new model from
the MHC class II-restricted Th1 dominated classical EAE
models in rodents and marmosets induced with CFA. To
analyze this in further detail we have tested to what
extent modulation of Th1-mediated pathogenic mecha-
nisms by treatment with human IFNγ modulates the
disease course in this new model. Our prior expectation
was analogous to the situation in mouse models of EAE
(Sanvito et al. 2010) or of collagen-induced arthritis
(Mauritz et al. 1988), presence of high IFNγ levels during
disease induction stimulated the disease, whereas late
administration is suppressive. An explanation for the early
stimulation is a generalized immune stimulatory effect,
whereas the late suppressive effect might be that injection
of IFNγ suppresses production of IFNγ at the tissue level
(Brok et al. 1993).
In the marmoset EAE model, administration of IFNγ
between psd 0 and 25 exerted modulatory effects on
several immunological parameters demonstrating in vivo
biological activity, but had no systemic effect on the time
of onset or the clinical course of the EAE model.
Importantly, different from the observation in MS
patients (Panitch et al. 1987), administration of IFNγ
did not aggravate clinical signs.
The body weight loss is a useful objective disease
parameter, which is usually attributed to a systemic
metabolic effect of inflammatory mediators such as TNFα,
IL-6 or IFNγ, the cachectic syndrome (Cahlin et al. 2000).
The body weight loss in the MOG34-56/IFA model is less
serious than in the EAE models induced with CFA and
shows a high interindividual variability that is inherent to
the outbred nature of the marmoset EAE model. Mean body
weight measurements of the early IFNγ-treated animals
remained stable between psd 0 and 56, whereas a decrease
was observed in the control and late treated animals, which
262 J Neuroimmune Pharmacol (2012) 7:253–265were untreated during this time period. Late treatment with
IFNγ during the episode psd 56 to 81 had no clear effect on
the mean weight loss. It is tempting to speculate that the
variable clinical effect of IFNγ may be due to a similar
variation in immunopathogenic profile as observed in MS
patients (Axtell et al. 2010).
Another level of modulation by IFNγ was the
skewing of the IgM or IgG ratio of anti-MOG peptide
antibodies, i.e. the increase of IgM and decrease of IgG.
This was less evident in the late treatment group.
Although proliferation of PBMC remained relatively
low, it was affected by the IFNγ treatment. The time to
exceed the SI threshold 3 was delayed in the early
treatment group. Moreover, PBMC from IFNγ treated
monkeys proliferated less against MOG34-56 and rhMOG
than PBMC from control monkeys during late stage
disease, i.e. after psd 100. However, the reactivity profiles
of MNC from the lymphoid organs were largely compa-
Fig. 6 Cytokine expression
measured by qPCR. mRNA
was extracted from PBMC,
spleen and ALN that were
aseptically collected at necropsy
and from PBMC collected at
2 weeks interval during the
disease course. Primers with the
corresponding probes as detailed
in Table 2 were used for qPCR.
aI FNγ, IL-17, IL10, IL-1β,
TNFα and IL-2 mRNA level in
PBMC, spleen and ALN were
determined in all three groups.
Data depicted in the graph were
expressed relative to the house-
hold gene ABL (see Materials &
Methods). b CD3 expression
was also determined in PBMC,
spleen and ALN. Mann–
Whitney U test: *p<0.05;
**p<0.001
J Neuroimmune Pharmacol (2012) 7:253–265 263rable between the three groups. At the level of cytokine
production no effect of IFNγ treatment was observed,
only the lymphocytes from the various organs within each
group showed significant differences. Differences between
PBMC, spleen and ALN were mainly found in the
expression of IL-10, IL-1β,T N F α and IL-2.
Treatment with human IFNγ exerts several modulatory
effects on immune parameters in the new EAE model, in
particular when the cytokine is administered during the
induction of the pathogenic process. These effects are
more subtle than those observed in regular EAE models
induced with CFA. Despite these immunomodulatory
effects, IFNγ treatment had no clear effect on the
severity nor the course of neurological disease. We
would like to propose as explanation that the IL-17A
producing cytotoxic CD3
+CD4
+/CD8
+CD56
+CD16
- Tc e l l s
that form the core pathogenic factor in the MOG34-56/IFA
EAE model are not affected by IFNγ treatment.
In conclusion, human IFNγ is biologically active on
several immune parameters in the marmoset EAE model.
Nevertheless, we observed neither of the early nor the late
treatment a detectable effect on the severity or course of
EAE. This marks a clear difference with rodent EAE
models. We also did not observe aggravation of clinical
signs as was observed in relapsing remitting MS patients.
Our interpretation of this discrepancy is that the T cells that
cause pathology and neurological deficit in this model are
committed effector memory cells (Jagessar et al. 2011,i n
press), which exert their activity in the late progressive
phase of the disease (Kap et al. 2008). Taken together the
conclusion is warranted that Th1 cells do not have a
detectable role in the new model.
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